Cerebral Tumors
Conditions
Keywords
optical biopsy
Brief summary
Purpose of the study is to answer the question whether confocal laser endomicroscopy (CLE, also named 'optical biopsy') might improve the results of medically necessary neurosurgery to prove practicability, safety and harmlessness of CLE during neurosurgical procedures
Detailed description
In patients requiring neurosurgical oncological Intervention using endoscopic devices, a mini laser probe will be administered through the endoscopic device to characterize in vivo the tissue by thousandfold magnification down to the cellular level (so-called optical biopsy). Magnification is presented to the neurosurgeon in time to better differentiate between healthy and pathological tissue. Post-surgery results of in-vivo Differentiation will then be compared to histocytopathological findings.
Interventions
OTHERCellvizio mini laser probe
Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
Sponsors
Charalampaki, Cleopatra, M.D.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* patients administered to the department of neurosurgery requiring neurosurgery due to either diagnosed gliomata (40 patients) or diagnosed subcranial tumors adjacent to or already invading neuronal structures (20 patients) * patients having given informed consent
Exclusion criteria
* severe concomitant diseases probably negatively influencing the participation in this clinical trial * cardial infarction or stroke within the preceding 12 months * Treatment resistant hypertonus (systolic blood pressure \>200 mmHg or diastolic blood pressure \>120 mmHg or a combination of both * Pulmonic diseases that might result in an advanced risk for anesthetic measurements * Patients being vaccinated with live vaccines (14 days Prior) or contra Influenza (7 days Prior) to start of the study * All concomitant findings that might increase in the eyes of the investigator the risk of participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| post-surgery comparison of in-vivo tissue characterization with ex-vivo histocytopathology | duration of hospital stay, an expected average of 7 days |
Secondary
| Measure | Time frame |
|---|---|
| proof of complete removal of pathologic tissue within healthy tissue | during surgical procedure, an expected average time of three hours |
| optimal tumour remission or reduction after 3 months post-surgery proven by respective diagnostic measurements | 3 months post surgery |
| Composite measure of missing iatrogenic damage of healthy neuronal structures and preservation of functionality of healthy tissue | individual post-surgery controls, an expected average of up to 7 days |
Countries
Germany
Outcome results
None listed